New strategies for the treatment of type 2 diabetes

Journal of the American Dietetic Association

Volumn 99, Issue 3, 1999, Pages 329-334

  Lipkin, Edward ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; ACETOHEXAMIDE; ALPHA GLUCOSIDASE INHIBITOR; BIGUANIDE DERIVATIVE; CHLORPROPAMIDE; CIGLITAZONE; ENGLITAZONE; GLIBENCLAMIDE; GLIPIZIDE; INSULIN; METFORMIN; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; SULFONYLUREA DERIVATIVE; THIAZOLIDINE DERIVATIVE; TOLBUTAMIDE; TROGLITAZONE;

DIABETES MELLITUS; DRUG INDUCED DISEASE; DRUG MECHANISM; EXERCISE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERINSULINEMIA; HYPOGLYCEMIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; INSULIN TREATMENT; LACTIC ACIDOSIS; LIVER TOXICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NUTRITION; ORAL DRUG ADMINISTRATION; REVIEW; TREATMENT INDICATION;

EID: 0033009105     PISSN: 00028223     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-8223(99)00083-8     Document Type: Review

References (47)

1. American Diabetes Association. Screening for type 2 diabetes. Diabetes Care. 1998;21(suppl 1):S20-S22.
2. American Diabetes Association. Third-party reimbursement for diabetes care, self-management education, and supplies. Diabetes Care. 1998;21(suppl 1):S86-S87.
3. Eastman RC, Siebert CW, Harris M, Gorden P. Implications of the Diabetes Control and Complications Trial. J Clin Endocrinol Metab. 1993;77:1105-1107.
4. Strowig WM, Raskin P. Glycemic control and the complications of diabetes. After the Diabetes Control and Complications Trial. Diabetes Rev. 1995;3:237-257.
5. DCCT Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977-986.
6. Kahn CR. Insulin action, diabetogenes, and the cause of type II diabetes. Diabetes. 1994;43:1066-1084.
7. Knowler WC, Narayan KMV, Hanson RL, Nelson RG, Bennett PH, Tuomilehto J, Schersten B, Pettitt DJ. Preventing non-insulin-dependent diabetes. Diabetes. 1995;44:483-488.
8. Olefsky JM. Insulin resistance in non-insulin-dependent diabetes mellitus. Curr Opin Endocrinol Diab. 1995;2:290-299.
9. Yki-Järvinen H. Pathogenesis of non-insulin-dependent diabetes mellitus. Lancet 1994;343:91-95.
10. Kelley DE, Wing R, Buonocore C, Sturis J, Polonsky K, Fitzsimmons M. Relative effects of calorie restriction and weight loss in non-insulin-dependent diabetes mellitus. J Clin Endocrinol Metab. 1993;77:1287-1293.
11. Ludvik B, Nolan JJ, Baloga J, Sacks D, Olefsky J. Effect of obesity on insulin resistance in normal subjects and patients with NIDDM. Diabetes. 1995;44:1121-1125.
12. American Diabetes Association. Standards of medical care for patients with diabetes mellitus. Diabetes Care. 1998;21(suppl):S23-S31.
13. Position statement: nutrition recommendations and principles for people with diabetes mellitus. Diabetes Care. 1994;17:490-518.
14. Nutrition management of diabetes mellitus. In: Manual of Clinical Dietetics. 4th ed. Chicago, Ill: American Dietetic Association; 1992:597-616.
15. Franz MJ, Horton ES, Bantle JP, Beebe CA, Brunzell JD, Coulston AM, Henry RR, Hoogwerf BJ, Stacpoole PW. Nutrition principles for the management of diabetes and related complications. Diabetes Care. 1994;17:490-518.
16. Garg A. High-monounsaturated-fat diets for patients with diabetes mellitus: a meta-analysis. Am J Clin Nutr. 1998;57(suppl):577S-582S.
17. Kushi LH, Lenart EB, Willett WC. Health implications of Mediterranean diets in light of contemporary knowledge, 2: Meat, wine, fats, and oils. Am J Clin Nutr. 1995;61(suppl)1416S-1427S.
18. Wing RR, Venditti E, Jakicic JM, Polly BA, Lang W. Lifestyle intervention in overweight individuals with a family history of diabetes. Diabetes Care. 1998;21:350-359.
19. U.K. Diabetes Study Group. U.K. prospective diabetes study 16: overview of 6 years' therapy of type II diabetes. Diabetes. 1995;44:1249-1258.
20. U.K. Prospective Diabetes Study Group. U.K. prospective diabetes study 13: relative efficacy of randomly allocated diet, sulfonylurea, insnlin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for 3 years. BMJ. 1995;310:83-88.
21. U.K. Prospective Diabetes Study Group U.K. prospective diabetes study 7: response of fasting plasma glucose to diet therapy in newly presenting type II diabetic patients. Metabolism. 1990;39:905-912.
22. Yamanouchi K, Shinozaki T, Chikada K, Nishikawa T, Ito K, Shimizu S, Ozawa N, Suzuki Y, Maeno H, Kato K, Oshida Y, Sato Y. Daily walking combined with diet therapy is a useful means for obese NIDDM patients not only to reduce body weight but also to improve insulin sensitivity. Diabetes Care. 1995;18:775-778.
23. Cardiac valvulopathy associated with exposure to fenfluramine or dexfenfluramine: US Department of Health and Human Services Interim Public Health Recommendations. MMWR Morbid Mortal Week Rep. 1997;46:1061-1066.
24. Marks SJ, Moore NR, Clark ML, Strauss BJG, Hockaday TDR. Reduction of visceral adipose tissue and improvement of metabolic indices: effect of dexfenfluramine in NIDDM. Obes Res. 1996;4:1-7.
25. Gerrich JE. Oral hypoglycemic drugs. N Engl J Med. 1989; 321:1231-1245.
26. Group LC. Sulfonylureas in NIDDM. Diabetes Care. 1992;15:737-754.
27. Balley DJ, Turner RC. Metformin. N Engl J Med. 1996;334:574-579.
28. Johnson JL, Wolf SL, Kabadi UM. Efficacy of insulin and sulfonylurea combination therapy in type II diabetes. A meta-analysis of the randomized placebo-controlled trials. Arch Intern Med. 1996;156:259-264.
29. Crofford OB. Metformin. N Engl J Med. 1995;333:588-589.
30. Lee A, Morley JE. Metformin decreases food consumption and induces weight loss in subjects with obesity with type II non-insulin-dependent diabetes. Obes Res. 1998;6:47-53.
31. DeFronzo RA, Goodman AM. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. N Engl J Med. 1995;333:541-549.
32. Stumvoli M, Nurjhan N, Perriello G, Daily G, Gerrich JE. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N Engl J Med. 1995;333:550-554.
33. Calle-Pascual AL, Garcia-Honduvilla J, Manin-Alvarez PJ, Vara E, Calle JR, Munguira ME, Maranes JP. Comparison between acarbose, metformin, and insulin treatment in type 2 diabetic patients with secondary failure to sulfonylurea treatment. Diabetes Metab (Paris). 1995;21:256-260.
34. Dicicco R. Allen A, Jorkasky D, Carr A, Frred M. Lack of pharmacokinetic drug interaction between rosiglitazone (BRL 49653C) and metformin [abstract]. Clin Pharmacol Ther. 1998;63:155.
35. Whitcomb RW, Saltiel AR. Thiazolidinediones. Exp Opin Invest Drugs. 1995;4:1299-1309,
36. Spiegelman BM, PPAR-γ: adipogenic regular and thiazolidinedione receptor. Diabetes. 1998;47:507-514.
37. Burant CF, Sreenan S, Hirano K, Tai TA, Lohmiller J, Lukens J, Davidson NO, Ross S, Graves RA. Troglitazone action is independent of adipose tissue. J Clin Invest. 1997;100:2900-2908.
38. Iwamoto Y, Kuzuya T, Matsuda A, Awata T, Kumakura S, Inooka G, Shiraishi I. Effect of new oral antidiabetic agent CS-045 on glucose tolerance and insulin secretion in patients with NIDDM. Diabetes Care. 1991;14:1083-1086.
39. Nolan JJ, Ludvik B, Beerdsen P, Joyce M, Olefsky J. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N Engl J Med. 1994;331:1188-1193.
40. Park KS, Ciaraldi TP, Lindgren K, Abrams-Carter L, Mudaliar S, Nikoulina SE, Tufari SR, Veerkamp JH, Vidal-Puig A, Henry RR. Troglitazone effects on gene expression in human skeletal muscle of type II diabetes involve up-regulation of peroxisome proliferator-activated receptor-gamma. J Clin Endocrinol Metab. 1988;83:1636-1643.
41. Prigeon RL, Kahn SE, Porte D Jr. Effect of troglitazone on B cell function, insulin sensitivity, and glycemic control in subjects with type 2 diabetes mellitus. J Clin Endocrinol Metab. 1998;83:819-823.
42. Inzucchi SE, Maggs DG, Spolett GR, Page SL, Rife FS, Walton V, Shulman GI. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. N Engl J Med. 1998;338:867-872.
43. Schwartz S, Raskin P, Fonseca V, Graveline JF, for the Troglitazone and Exogenous Insulin Study Group. Effect of troglitazone in insulin-treated patients with type II diabetes mellitus. N Engl J Med. 1998; 338:861-866.
44. Edelman SV, Henry RR. Insulin therapy to normalize glycosylated hemoglobin in type II diabetes. Diabetes Rev. 1995;3:308-334.
45. Levy J, Vandenberg M, Grunberger G. Insulin versus glipizide treatment in patients with non-insulin-dependent diabetes mellitus. Effects on blood pressure and glucose tolerance. Am J Hypertens. 1995;8:445-453.
46. Hayward RA, Manning WG, Kaplan SH, Wagner EH, Greenfield S. Starting insulin therapy in patients with type 2 diabetes. Effectiveness, complications, and resource utilization. JAMA. 1997;278:1663-1669.
47. Nathan DM. Insulin treatment of noninsulin-dependent diabetes mellitus. In: Porte D Jr, Sherwin RS, eds. Ellenberg & Rifkin's Diabetes Mellitus. Stamford, Conn: Appleton & Lange; 1997:735-743.